BioCentury | May 3, 2004
Finance

Almost running the table

...$2.53) -9% -185.9 $1,880.0 EPS excludes a tax gain of $0.15 from the acquisition of Kinetek...
BioCentury | Apr 27, 2004
Financial News

QLT reports earnings

...first quarter GAAP EPS of $0.34, which includes a tax gain from its acquisition of Kinetek...
BioCentury | Apr 5, 2004
Company News

Kinetek, QLT deal

...Kinetek for an aggregate cash payment of about $2.7 million. In June 2001, QLT and Kinetek...
...kidney diseases. QLT expects the deal to increase 2004 EPS by $0.10 to $0.84- $0.96. Kinetek Pharmaceuticals Inc....
BioCentury | Sep 15, 2003
Company News

Inex board of directors update

...and principal at Management Associates; and James Hudson, former SVP of finance and CFO at Kinetek Pharmaceuticals Inc....
BioCentury | Feb 25, 2002
Company News

Atugen, Kinetek deal

...cellular delivery technologies to knock-down the expression of signal transduction kinase targets supplied by Kinetek. Kinetek...
...GeneBloc molecules to validate the gene function of the targets. atugen AG , Berlin, Germany Kinetek Pharmaceuticals Inc....
BioCentury | Feb 20, 2002
Company News

Kinetek, atugen GeneBloc deal

...technologies to knock-down the expression of signal transduction kinase targets supplied by Kinetek (Vancover, B.C.). Kinetek...
BioCentury | Dec 24, 2001
Strategy

Line of succession

...treating either alopecia or benign prostatic hyperplasia. Earlier this year, QLTI signed a deal with Kinetek Pharmaceuticals Inc....
BioCentury | Jun 11, 2001
Company News

Kinetek, QLT deal

...QLT and Kinetek will develop signal transduction inhibitors to treat ophthalmic, immune system and kidney diseases...
...to treat ophthalmic, immune system and kidney diseases. QLT invested C$11 million (US$7.2 million) in Kinetek...
...initial equity investment, Kinetek will receive a C$5.5 million investment from certain existing Kinetek shareholders. Kinetek Pharmaceuticals Inc....
BioCentury | Jun 7, 2001
Company News

QLT, Kinetek signal transduction deal

...QLT (TSE:QLT; QLTI) and Kinetek (Vancouver, B.C.) will develop signal transduction inhibitors to treat ophthalmic, immune...
...to treat ophthalmic, immune system and kidney diseases. QLT invested C$11 million (US$7.2 million) in Kinetek...
...with QLT's initial equity investment, Kinetek will receive a C$5 million investment from certain existing Kinetek...
BioCentury | Feb 5, 2001
Company News

Kinetek management update

Kinetek Pharmaceuticals Inc., Vancouver, B.C. Business: Metabolic, Cancer Promoted: Jasbinder Sanghera to CSO from VP of drug discovery; and Gabe Kalmar to VP of R&D operations from VP of corporate development and strategic planning WIR...
Items per page:
1 - 10 of 35
BioCentury | May 3, 2004
Finance

Almost running the table

...$2.53) -9% -185.9 $1,880.0 EPS excludes a tax gain of $0.15 from the acquisition of Kinetek...
BioCentury | Apr 27, 2004
Financial News

QLT reports earnings

...first quarter GAAP EPS of $0.34, which includes a tax gain from its acquisition of Kinetek...
BioCentury | Apr 5, 2004
Company News

Kinetek, QLT deal

...Kinetek for an aggregate cash payment of about $2.7 million. In June 2001, QLT and Kinetek...
...kidney diseases. QLT expects the deal to increase 2004 EPS by $0.10 to $0.84- $0.96. Kinetek Pharmaceuticals Inc....
BioCentury | Sep 15, 2003
Company News

Inex board of directors update

...and principal at Management Associates; and James Hudson, former SVP of finance and CFO at Kinetek Pharmaceuticals Inc....
BioCentury | Feb 25, 2002
Company News

Atugen, Kinetek deal

...cellular delivery technologies to knock-down the expression of signal transduction kinase targets supplied by Kinetek. Kinetek...
...GeneBloc molecules to validate the gene function of the targets. atugen AG , Berlin, Germany Kinetek Pharmaceuticals Inc....
BioCentury | Feb 20, 2002
Company News

Kinetek, atugen GeneBloc deal

...technologies to knock-down the expression of signal transduction kinase targets supplied by Kinetek (Vancover, B.C.). Kinetek...
BioCentury | Dec 24, 2001
Strategy

Line of succession

...treating either alopecia or benign prostatic hyperplasia. Earlier this year, QLTI signed a deal with Kinetek Pharmaceuticals Inc....
BioCentury | Jun 11, 2001
Company News

Kinetek, QLT deal

...QLT and Kinetek will develop signal transduction inhibitors to treat ophthalmic, immune system and kidney diseases...
...to treat ophthalmic, immune system and kidney diseases. QLT invested C$11 million (US$7.2 million) in Kinetek...
...initial equity investment, Kinetek will receive a C$5.5 million investment from certain existing Kinetek shareholders. Kinetek Pharmaceuticals Inc....
BioCentury | Jun 7, 2001
Company News

QLT, Kinetek signal transduction deal

...QLT (TSE:QLT; QLTI) and Kinetek (Vancouver, B.C.) will develop signal transduction inhibitors to treat ophthalmic, immune...
...to treat ophthalmic, immune system and kidney diseases. QLT invested C$11 million (US$7.2 million) in Kinetek...
...with QLT's initial equity investment, Kinetek will receive a C$5 million investment from certain existing Kinetek...
BioCentury | Feb 5, 2001
Company News

Kinetek management update

Kinetek Pharmaceuticals Inc., Vancouver, B.C. Business: Metabolic, Cancer Promoted: Jasbinder Sanghera to CSO from VP of drug discovery; and Gabe Kalmar to VP of R&D operations from VP of corporate development and strategic planning WIR...
Items per page:
1 - 10 of 35